Damora Therapeutics completes move from Delaware to Cayman Islands

Damora Therapeutics, Inc. (NASDAQ: DMRA) announced on July 17, 2026 that it had completed its redomestication from Delaware to the Cayman Islands, a change effective July 16, 2026, as disclosed in a press release from the company describing itself as focused on care for patients with blood disorders.¹

Under the conversion, each share of the Delaware company's common stock became one Cayman ordinary share at $0.00001 par value, and each share of preferred stock converted into a corresponding series of Cayman preferred shares.¹ The move followed a shareholder vote: the board had already approved the redomestication, and stockholders ratified it at a special meeting held February 9, 2026.¹

Trading logistics shift slightly. Beginning July 20, 2026, Damora's ordinary shares will carry a new CUSIP, G2646Y104, while continuing to trade on Nasdaq under the same ticker, "DMRA."¹ The company said the redomestication itself does not change its underlying business, management team, obligations, assets, or liabilities.¹

Separately, the 8-K disclosed that on July 16, 2026, Damora entered into new indemnification agreements with its directors and executive officers, replacing prior agreements.¹ These agreements set terms for indemnification and expense advancement tied to the officers' and directors' service to the company or affiliated entities.¹

The filing also detailed procedural steps behind the conversion, including the filing of a Certificate of Conversion with Delaware's Secretary of State effective 4:45 p.m. Eastern time on July 16, 2026, alongside the filing of Cayman Islands memorandum and articles of association effective the same date.¹ Damora also filed certificates of designation in the Cayman Islands for its Series A, B, and C Non-Voting Convertible Preferred Shares, each effective July 16, 2026.¹